SNDX Stock Overview A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Syndax Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Syndax Pharmaceuticals Historical stock prices Current Share Price US$13.08 52 Week High US$25.34 52 Week Low US$12.75 Beta 0.84 1 Month Change -18.71% 3 Month Change -27.05% 1 Year Change -37.54% 3 Year Change -41.79% 5 Year Change 46.31% Change since IPO 8.91%
Recent News & Updates
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial Dec 10
Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting Dec 08
Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Nov 16
Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib Nov 13
Consensus revenue estimates increase by 197% Nov 12
Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting Nov 05 See more updates
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial Dec 10
Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting Dec 08
Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Nov 16
Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib Nov 13
Consensus revenue estimates increase by 197% Nov 12
Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting Nov 05
Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 29
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully Oct 14
Syndax Pharmaceuticals: Navigating Through A Pivotal Year Sep 20
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
Consensus revenue estimates fall by 21% Aug 01
Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia Jul 30
Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25 Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index
Consensus revenue estimates increase by 12% Jun 28
Syndax: Gearing Up For Launches Jun 21
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth Jun 20
SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress Jun 17
Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC Jun 08
Syndax Pharmaceuticals, Inc. Announces Board Changes May 16
Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Apr 09
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024 Apr 03
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Mar 28
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope Mar 28
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia Mar 27
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 19
Consensus EPS estimates fall by 23% Mar 05
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation Mar 04
Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 21 Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.
Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting Dec 13
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount? Nov 20
Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting Nov 03
Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program Oct 25
Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis Oct 05
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth Sep 27
Director notifies of intention to sell stock Aug 13
Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 26
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25
Director notifies of intention to sell stock Jul 13
Consensus revenue estimates decrease by 11%, EPS upgraded Jun 27
Director exercised options and sold US$715k worth of stock Jun 11
Director exercised options and sold US$794k worth of stock May 12
Syndax Pharmaceuticals, Inc. Announces Executive Changes May 10
President exercised options and sold US$695k worth of stock Apr 13
President exercised options and sold US$853k worth of stock Mar 15
Consensus EPS estimates fall by 21% Mar 07
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Feb 20
President exercised options and sold US$1.1m worth of stock Feb 09
Price target increased by 7.6% to US$34.44 Feb 01
Independent Director exercised options and sold US$616k worth of stock Jan 15 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock Dec 04
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer Dec 03
Insufficient new directors Nov 16
Consensus revenue estimates increase by 64% Nov 10
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021) Nov 04
Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias Nov 04
Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
CEO & Director exercised options and sold US$549k worth of stock Oct 05
President exercised options and sold US$4.4m worth of stock Sep 17
Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock Aug 27
Consensus forecasts updated Aug 15
Independent Director exercised options and sold US$331k worth of stock Aug 11
First half 2022 earnings released Aug 09
Syndax Pharmaceuticals Q2 2022 Earnings Preview Aug 07
Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 03
Insufficient new directors Aug 02
CEO & Director exercised options and sold US$464k worth of stock Jul 28
President exercised options and sold US$735k worth of stock Jul 06
Investor sentiment improved over the past week Jun 23
Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer Jun 14
Investor sentiment improved over the past week May 31
Consensus forecasts updated May 16
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 10
Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs Apr 08
President exercised options and sold US$486k worth of stock Apr 06
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 31
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 30
Consensus forecasts updated Mar 08
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 04
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 03
Syndax Pharmaceuticals, Inc. Announces Executive Changes Feb 25
Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24
Price target increased to US$31.67 Feb 16 Syndax Pharmaceuticals, Inc. Announces Executive Changes
Chief Medical Officer & Senior VP exercised options to buy US$131k worth of stock. Jan 04
President exercised options and sold US$462k worth of stock Dec 17 Shareholder Returns SNDX US Biotechs US Market 7D -6.1% -3.6% -2.4% 1Y -37.5% -2.6% 23.4%
See full shareholder returns
Return vs Industry: SNDX underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: SNDX underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is SNDX's price volatile compared to industry and market? SNDX volatility SNDX Average Weekly Movement 9.5% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SNDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SNDX's weekly volatility (9%) has been stable over the past year.
About the Company Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat.
Show more Syndax Pharmaceuticals, Inc. Fundamentals Summary How do Syndax Pharmaceuticals's earnings and revenue compare to its market cap? SNDX fundamental statistics Market cap US$1.12b Earnings (TTM ) -US$297.06m Revenue (TTM ) US$16.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SNDX income statement (TTM ) Revenue US$16.00m Cost of Revenue US$64.19m Gross Profit -US$48.19m Other Expenses US$248.87m Earnings -US$297.06m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.48 Gross Margin -301.21% Net Profit Margin -1,856.64% Debt/Equity Ratio 0%
How did SNDX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 05:01 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Syndax Pharmaceuticals, Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Jason Zemansky BofA Global Research Madhu Kumar B. Riley Securities, Inc.
Show 20 more analysts 
